Ambrosia Bio raises $100M for oral GLP-1 trial

Biotech firm secures funding for novel diabetes treatment approach.

Apr. 2, 2026 at 3:10pm

Got story updates? Submit your updates here. ›

Ambrosia Biosciences Inc., a Boulder-based biotech company, has closed a $100 million funding round to advance its oral glucagon-like peptide-1 (GLP-1) receptor agonist therapy for the treatment of type 2 diabetes.

Why it matters

GLP-1 therapies have emerged as a promising approach for managing type 2 diabetes, but current injectable formulations can be inconvenient for patients. Ambrosia's oral GLP-1 candidate could provide a more patient-friendly alternative if successful in clinical trials.

The details

The oversubscribed $100 million funding round will allow Ambrosia to initiate a Phase 2 clinical trial evaluating its proprietary oral GLP-1 receptor agonist. The company's lead candidate is designed to be taken as a daily pill, potentially improving adherence and accessibility compared to injectable GLP-1 therapies currently on the market.

  • Ambrosia Biosciences was founded in 2020.

The players

Ambrosia Biosciences Inc.

A Boulder-based biotech company developing an oral formulation of a glucagon-like peptide-1 (GLP-1) receptor agonist for the treatment of type 2 diabetes.

Got photos? Submit your photos here. ›

What’s next

Ambrosia plans to initiate a Phase 2 clinical trial to evaluate the safety and efficacy of its oral GLP-1 candidate in the coming months.

The takeaway

Ambrosia's successful funding round highlights the continued interest in innovative diabetes therapies, particularly those that can improve patient convenience and adherence through oral administration.